A drug discovery and development company focused on advancing novel approaches for severe respiratory conditions
The Company's year-end is 31 December (after 30 June 2011 it was changed to 31 December). We report our financial results on a half yearly basis.
Copies of the Report and accounts can be found here.
Reports and accounts